first quarter. Justin. Epidiolex Thank pleased in very you, report of continued to sales U.S. growth I'm and strength the
quarter were as caregivers of both sales $XX.X improve the $XXX.X transformational thousands of U.S. million hear year. the and to quarter the last to first health this professionals patients. equivalent continue lives to Epidiolex in to care how therapy compared million We from in feedback continues
the call, class. recall in QX on likely we seasonality to common QX will impact our the drug anti-epilepsy discussed You
While of growth. we patients plans we efforts in expected January quarter, did this showed through change see half minimal the resets a of managing the seasonality proactive sales Overall, requirements, strong March, believe particularly our February, rates. effect to to and out-of-pocket and refill in early support led reauthorization employer latter drop-off
March, the a was believe COVID-XX Epidiolex first As into quarter. we there took in prescription forward of hold not pulling do
of approve was, not Given XX-day recently, that health plans Epidiolex fills. majority scheduled, very until the do
we a indicator the an in that result, in for there growth significant XXXX. QX as see number As brand the revenue remains the potential
were retention consistent strength of starts and the patient prior with remains a quarter the New brand.
slight see the in dosing a We continue average quarter. during to increase
across discussed our varies different call, target adoption earnings As in segments. our Epidiolex of previous
top Our TRxs driving targets penetration in of and is of in prescribing nearly our have in of those XX% a with targets level QX. half written prescription
that the brand next to significant HCPs, team believe wave of for opportunity growth commercial for the our for key a in We and account continue focus is a over prescribers, XXXX. which X,XXX
saw we group penetration XX% increased deciles market filled. and prescription QX. HCP having volume with QX, During share nearly in added grew prescriber over All this prescriptions
As face-to-face virtual ability we field setting, with for mid-March, engage the activities, suspended the basis. to, virtual interact effects provide we team we of digital the COVID-XX core sales to lunch appropriate, learns. distribution a our our virtual optimized all but along on with updated transitioned sales started to in to to Once interactive where and able materials take we hold were customers with have in continued
previously also to of were scheduled in programs XX% online We live speaker an platform. converting successful
you quality on identifying are place would we seen taking engagements from Epidiolex. meaningful the in significant the are that and conversations While have focused the robust engagements, patients decline benefit that can a of of number expect, as
initiating physicians April and, physicians of that we general, person their a new more through epilepsy to therefore, patient the currently patients challenging environment therapies To been in are that initiations to date, is, the in visiting telemedicine. and This to the said, product in performance COVID-XX recognize Epidiolex in that the many continued has had must for second even new we impact accustomed during see not a strong We that stay few solid quarter. is less are feel That COVID-XX attributes has environment. feared. than
the Market to quarter Looking Epidiolex use. more at prior broadly. increase the in continued first to COVID-XX show research market intent to conducted
our these with of While research coming DS from Epidiolex identified use the for use grow approximately in intent other interviewed majority using in is reported epilepsies to HCPs and of other LGS, refractory segments. XX% the
focus of account the team in long-term a on segment, care of QX. completed and XXXX our our build-out One the we initiatives is in
execute their interact network. quarter. educate out long-term the with plan care the This and pharmacists care education been independent launched allows and Epidiolex and said, organization group plan us during virtual collaboration largest programs That we consultant know, rolling this by particularly on has pandemic. we a associated We purchasing X,XXX-plus audience the impacted to long-term month. hard As long-term all to started care pharmacies next to have our within
COVID-XX, long-term Looking ahead patients for for caregivers. recent development and benefits will health the a that action care DEA to beyond providers, the have deschedule brand is Epidiolex positive and
we be this While a many this at states descheduling and later will ongoing work is remains now federal completed administrative there complete within hope year. level,
seizures include label are about the July We with end expansion expected at associated TSC. to the of excited
activities teams market launch extensive Our into a are with that having prelaunch position conducted disease all state. our marketing and successful advisory for research, medical, will underway this access other market boards preparations well us launch-planning and
approval. they when for are data, for our circumstances, Epidiolex aware be research beyond. COVID-XX and the patients most population. remind a or we an the TSC expansion second we addressable population we of diagnosed highly patient TSC I not will that This clinicians opportunity growth of currently seizures is either you that Regardless receive of of sales year virtual to clearly want is launch the estimated team this outreach planning within market number from environment. in-person half commercial to have important suggests believe receptive our this for doubling an the our in to are XX,XXX, the the Interestingly, and XX,XXX of
We in epilepsies. in evolving around Turning broader year momentum our continued LGS for and intractable new started with payer initiatives. to DS, Epidiolex discussions the the coverage our
to using or PAs appropriate. these with where engage of payers are goal moving and the step interactions edits We to simple easing removing
Epidiolex inclusion we near plans the upon been foresee have now approval. their most Our within conversations These indication also into TSC of TSC include productive and of conversations the inclusion immediate very future policies.
review of Epidiolex. via This review show appropriate and DS, of plan's appeals and The of utilization plan's process. the TSC the being coincides nicely data approved anticipated current their with the majority utilization claims or other to LGS are in continues and intractable epilepsy peer-to-peer vast approval use
remainder of had that COVID-XX payer last of impact year. and remain While expand on important weeks, throughout will evolve policy meetings some an the the confident we the has scheduling X the in payer
sales patients. indication. seizure among the momentum discussions Intent in U.S. see In to has the opening we unmet significantly through medicine XXXX. opportunity to heading And proven are well to HCPs the conclusion, and positioned reductions the treatment-resistant few continuation increase remains addresses high, launch to of of in meaningful significant provide the the we remainder prescribing towards next and expect are sustained need in expand access. of further months, of payer itself TSC otherwise This
patients need. We serving benefit that to comforted on focused are and this families providers continues our be time Epidiolex in and and continue patients during providing to extraordinary
on progress Chris an manufacturing. turn over update call I'll and Now to the to provide Europe in
